[Clinical experience with omalizumab in patients with severe asthma. Real-world data].

Background: Omalizumab is a monoclonal antibody that is prescribed in a stepwise addition regimen for the treatment of severe asthma.

Objective: To report the experience of patients with severe asthma who were given omalizumab in accordance with international guides, in a context of real-world data.

Methods: Open, analytical, cross-sectional, retrospective, observational clinical study with real-world data.